



Kuros Invites to the Annual Shareholders' Meeting 2016

May 26, 2016

Kuros Biosciences Ltd ("Kuros") today announced that the Annual Shareholders' Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Company's offices in Schlieren/Zurich (Switzerland). The Board of Directors proposes to carry out a reverse stock split at the ratio of 100 to 1 and to amend the Articles of Association accordingly.

Schlieren (Zurich), Switzerland, May 26, 2016

The capital restructuring measures in 2015 and 2016 resulted in a nominal value of CHF 0.01 per registered share. To simplify the trading and to increase the shares' attractiveness for investors, the Board proposes to carry out a reverse stock split at the ratio of 100 to 1 with the effect that 100 registered shares with a nominal value of CHF 0.01 each will be exchanged into 1 new (merged) registered share with a nominal value of CHF 1.00. The current shareholders and founders Dr. Jeffrey Hubbell and Didier Cowling have committed for no consideration to providing the other shareholders with the number of shares required in connection with the reverse stock split to enable the allocation of a rounded number of shares to every shareholder. As a result, each existing shareholder will receive at least one share and in any event, a rounded number of shares.

The nominal value of the shares that may be issued under the conditional and the authorized capital is to be changed from CHF 0.01 to CHF 1.00 as well to enable the future issuance of a round number of shares.

Messrs Dominik Ellenrieder and Vincent Ossipow do not stand for re-election as member of the Board. The Board of Directors proposes to elect Leanna Caron as new member of the Board. Mrs Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare. A healthcare executive for the past 20 years, she developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Mrs Caron received her Pharmacy degree from the University of Toronto and her MBA from Concordia and Cornell Universities.

The formal invitation to the meeting will be sent out within the next few days and can also be downloaded from the following website <http://www.kuros.ch/uploads/2016/AGM2016.pdf>

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information regarding Kuros is available at www.kuros.ch.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Kuros Biosciences Ltd

Harry Welten, MBA

Chief Financial Officer

Tel: +41 44 733 46 46

harry.welten@kuros.ch